Clinical Trials Logo

Clinical Trial Summary

A Phase 2 study to evaluate the clinical activity, safety, and potentially predictive biomarker profile of ZN-c3 in subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer


Clinical Trial Description

A Phase 2 study to evaluate the clinical activity, safety, and potentially predictive biomarker profile of ZN-c3 in subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05128825
Study type Interventional
Source K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Contact
Status Suspended
Phase Phase 2
Start date February 17, 2022
Completion date October 31, 2025